Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.61 |
| ▸ | STK17A | Q9UEE5 | 7/20 | 0.60 |
| ▸ | SYK | P43405 | 4/20 | 0.60 |
| ▸ | STK17B | O94768 | 4/20 | 0.60 |
| ▸ | JAK2 | O60674 | 5/20 | 0.53 |
| ▸ | JAK1 | P23458 | 3/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311536 | 0.92 | STK17A (0.61) | JAK3STK17ASYKSTK17BCSNK2A1 | |
| SCHEMBL3344183 | 0.91 | STK17A (0.60) | JAK3STK17ASYKSTK17BCSNK2A1 | |
| SCHEMBL13420319 | 0.85 | STK17A (0.66) | STK17ASTK17B | |
| SCHEMBL3448215 | 0.84 | STK17A (0.62) | STK17ASTK17B | |
| SCHEMBL3449421 | 0.82 | STK17A (0.52) | JAK3STK17ASYKSTK17BJAK2 | |
| SCHEMBL10243784 | 0.82 | SYK (0.70) | JAK3SYKJAK2JAK1 | |
| SCHEMBL3344195 | 0.81 | STK17A (0.59) | JAK3STK17ASTK17BJAK2JAK1 | |
| SCHEMBL913524 | 0.80 | JAK3 (0.61) | JAK3SYKJAK2JAK1 | |
| SCHEMBL3449939 | 0.80 | STK17A (0.52) | JAK3STK17ASTK17BJAK2JAK1 | |
| SCHEMBL13312760 | 0.80 | STK17A (0.52) | JAK3STK17ASTK17BJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | JAK3 2419/4885STK17A 1984/4885SYK 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.